Table 2.
Cardiac Function Measured by Echocardiography
| Group | n | LVEF (%) | LVDs (mm) | LVDd (mm) | CO (L/min) | HR (bpm) | LVFS (%) |
|---|---|---|---|---|---|---|---|
| Sham | 6 | 90.00±1.41 | 2.43±0.15 | 5.57±0.16 | 1.52±0.18 | 485±47 | 55.67±1.86 |
| CME | 6 | 57.50±4.97* | 5.48±0.22* | 7.43±0.19* | 0.84±0.16* | 430±49* | 26.50±3.0* |
| Low | 6 | 73.83±2.48*#a | 3.90±0.11*#a | 6.30±0.19*#a | 1.04±0.08*#a | 432±19 | 37.67±1.86*#a |
| High | 6 | 85.67±3.14# | 3.07±0.28*# | 6.07±0.14*# | 1.36±0.18# | 454±53 | 49.50±4.09# |
Notes: Alprostadil injection improved cardiac function following CME. The results are presented as the mean±standard deviation (SD), the values were averaged from three cardiac cycles. *P<0.05, compared with Sham group; #P<0.05, compared with CME group; aP<0.05, compared with High group.
Abbreviations: CME, coronary microembolization; Low, CME plus alprostadil injection (2 μg/kg); High, CME plus alprostadil injection (4 μg/kg); LVEF, left ventricular ejection fraction; LVDd, left ventricular end-diastolic diameter; LVFS, left ventricular fraction shortening; LVDs, left ventricular systolic diameter; CO, cardiac output; HR, heart rate.